GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GreenLight Biosciences Holdings PBC (NAS:GRNA) » Definitions » Cash Ratio

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Cash Ratio : 1.04 (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GreenLight Biosciences Holdings PBC Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. GreenLight Biosciences Holdings PBC's Cash Ratio for the quarter that ended in Mar. 2023 was 1.04.

GreenLight Biosciences Holdings PBC has a Cash Ratio of 1.04. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for GreenLight Biosciences Holdings PBC's Cash Ratio or its related term are showing as below:

GRNA' s Cash Ratio Range Over the Past 10 Years
Min: 0.5   Med: 1.91   Max: 6.83
Current: 1.04

During the past 4 years, GreenLight Biosciences Holdings PBC's highest Cash Ratio was 6.83. The lowest was 0.50. And the median was 1.91.

GRNA's Cash Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.9 vs GRNA: 1.04

GreenLight Biosciences Holdings PBC Cash Ratio Historical Data

The historical data trend for GreenLight Biosciences Holdings PBC's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GreenLight Biosciences Holdings PBC Cash Ratio Chart

GreenLight Biosciences Holdings PBC Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Ratio
4.53 6.83 0.50 1.91

GreenLight Biosciences Holdings PBC Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.82 0.80 3.03 1.91 1.04

Competitive Comparison of GreenLight Biosciences Holdings PBC's Cash Ratio

For the Biotechnology subindustry, GreenLight Biosciences Holdings PBC's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GreenLight Biosciences Holdings PBC's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GreenLight Biosciences Holdings PBC's Cash Ratio distribution charts can be found below:

* The bar in red indicates where GreenLight Biosciences Holdings PBC's Cash Ratio falls into.



GreenLight Biosciences Holdings PBC Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

GreenLight Biosciences Holdings PBC's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=68.097/35.56
=1.91

GreenLight Biosciences Holdings PBC's Cash Ratio for the quarter that ended in Mar. 2023 is calculated as:

Cash Ratio (Q: Mar. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=32.35/31.187
=1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GreenLight Biosciences Holdings PBC  (NAS:GRNA) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


GreenLight Biosciences Holdings PBC Cash Ratio Related Terms

Thank you for viewing the detailed overview of GreenLight Biosciences Holdings PBC's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
GreenLight Biosciences Holdings PBC is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.
Executives
Deval L Patrick other: See Remarks BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Dennis A. Clarke other: Member of 13D group owning 10% 6 FERNWAY TERRACE, WINCHESTER MA 01890
Cummings Foundation, Inc. other: Member of 13D group owning 10% 200 WEST CUMMINGS PARK, WOBURN MA 01801
Eric Senior Anderson other: Member of 13D group owning 10% 25 N HILL ROAD, WESTOVER MA 01886
Mls Capital Fund Ii Lp other: See remarks C/O MLSC II (GP) (LABUAN) LLP, ONE MARKET ST SUITE 3525, SAN FRANCISCO CA 94105
Chelt Trading Ltd other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 3RD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Highview Trust other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Montealegre Lacayo Jaime Javier other: Member of 13D Group APARTADO 15-1250, ESCAZU G2
Furneaux Capital Holdco, Llc other: Member of 13D group 1 MARINA PARK DRIVE, BOSTON MA 02210
Lewis & Clark Plant Sciences Fund I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Lewis & Clark Ventures I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Matthew Allen Walker director, 10 percent owner C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Martha Schlicher director C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Marta Ortega-valle other: Member of 10% owner group C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Builders Vision, Llc 10 percent owner 110 NW 2ND STREET SUITE 300, BENTONVILLE AR 72712

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Headlines

From GuruFocus

GreenLight Biosciences announces $109 million financing

By PurpleRose PurpleRose 08-12-2022